Jacobs Levy Equity Management
ZNTL icon

Jacobs Levy Equity Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jacobs Levy Equity Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-124,525
Closed -$168K – 1075
2025
Q4 		$168K Sell
124,525
-576,051
-82% -$838K ﹤0.01% 891
2025
Q3 		$1.06M Sell
700,576
-157,006
-18% -$235K ﹤0.01% 703
2025
Q2 		$995K Buy
857,582
+508,617
+146% +$671K ﹤0.01% 759
2025
Q1 		$555K Buy
348,965
+116,907
+50% +$252K ﹤0.01% 905
2024
Q4 		$703K Buy
+232,058
New +$761K ﹤0.01% 765

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Jacobs Levy Equity Management's ZNTL Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 124,525 shares — an estimated $168K sold.

Jacobs Levy Equity Management first reported a position in ZNTL in Q4 2024 and held it in 5 quarters. The position peaked at $1.06M in Q3 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 124,525 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $168K.
  • Jacobs Levy Equity Management first reported a position in Zentalis Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Zentalis Pharmaceuticals position peaked at $1.06M in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.